Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver

Pharmacogenetics

Volumn 8, Issue 5, 1998, Pages 391-401

  Shou, Magang ^a,d   Martinet, Michel ^b   Korzekwa, Kenneth R ^c   Krausz, Kristopher W ^a   Gonzalez, Frank J ^a   Gelboin, Harry V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Drug Metabolism and Pharmacokinetics   (France)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cDNA expression; Cytochrome P450; Drug metabolism; High performance liquid chromatography; Human liver; Monoclonal antibody; Taxotere

Indexed keywords

AFLATOXIN; ANTIHISTAMINIC AGENT; CIMETIDINE; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; GLUCOCORTICOID; IFOSFAMIDE; MONOCLONAL ANTIBODY; PACLITAXEL; RPR 104952; TAXOTERE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER MICROSOME; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; PACLITAXEL; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TAXOIDS;

EID: 0031716724     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199810000-00004     Document Type: Article

References (50)

1. Bissery MC, Vrignaud P, Bayssas M, Lavelle F. In vivo evaluation of taxotere (RP 56976, NSC 628503) in combination with cisplatinum, doxorubicin or vincristine. Proc Am Assoc Cancer Res 1992; 33:2645.
2. Bissery MC, Vrignaud P, Bayssas M, Lavelle F. Docetaxel (RP 56976, Taxotere) efficacy as a single agent or in combination against mammary tumors in mice. Proc Am Assoc Cancer Res 1994; 35:1946.
3. ®): a review of preclinical and clinical experience. Part I: preclinical experience. Anti-Cancer Drugs 1995; 6:339-355.
4. ™ (docetaxel). Cancer Surv 1993; 17:305-313.
5. Buters JT, Kozekwa KR, Kunze KL, Omata Y, Hardwick JP, Gonzalez FJ. cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Dispos 1994; 22:688-692.
6. Buters JTM, Shou M, Hardwick JP, Korzekwa KR, Gonzalez FJ. CDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NACPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification. Drug Metab Disp 1995; 23:696-701.
7. Colin M, Guenard D, Guéritte-Voégelin F, Potier P. Process for preparing derivatives of baccatin III and 10-deacetyl baccatin III. European Patent Application EP253 738 01/20/88; US patent 4924012; 1990.
8. ®). Tetrahedron Lett 1994; 50:10289-10298.
9. Cleland WW. Statistical analysis of enzyme kinetic data. Methods Enzymol 1979; 63:103-138.
10. Cresteil T, Monsarrat B, Alvinerie P, Tréluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54:386-392.
11. ® (TXT) (RP56976, NSC628503) in cancer patients. Proc Am Assoc Cancer Res 1993; 34:373.
12. Fumoleau P, Chevallier B, Kerbrat P, Dieras V, Azli N, Bayssas M, Van Glabbeke M. Current status of taxotere (docetaxel) as a new treatment in breast cancer. Breast Cancer Res Treat 1993; 33:39-46.
13. ®) metabolism in the rat in vivo and in vitro. Proc Am Assoc Cancer Res 1994; 35:428.
14. Gelboin HV. Cytochrome P450 and monoclonal antibodies. Pharmacol Rev 1993; 45:413-451.
15. Gelboin HV, Krausz KW, Goldfarb I, Buters JTM, Yang SK, Gonzalez FJ, et al. Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 1995; 50:1841-1850.
16. ®) disposition in the isolated perfused rat liver. Eur J Drug Met Pharmacokin 1994; 19(Suppl 2):29.
17. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994; 26:165-183.
18. Gonzalez FJ, Korzekwa KR. Cytochrome P450 expression systems. Ann Rev Pharmacol Toxicol 1995; 35:369-390.
19. Gonzalez FJ, Crespi CL, Gelboin HV. cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutat Res 1991a; 247:113-127.
20. Gonzalez FJ, Aoyama T, Gelboin HV. Expression of mammalian cytochrome P450 using vaccinia virus. Methods Enzymol 1991b; 206:85-92.
21. Guengerich TP, Gillam EMJ, Martin MV, Baba T, Kim BR, Raney KD, Yun CH. The importance of cytochrome P450 3 A enzymes in drug metabolism. In: Waterman MR and Hildebrand M, editors. Assessment of the use of single cytochrome P450 enzymes in drug research. Germany: Springer, Berlin; 1994, pp. 161-186.
22. Guéritte-Voegelein F, Guénard D, Lavelle F, Le Goff M-T, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991; 34:992-998.
23. Hanioka N, Korzekwa K, Gonzalez FJ. Sequence requirements for cytochromes P450IIA1 and P450IIA2 catalytic activity: evidence for both specific and non-specific substrate binding interactions through use of chimeric cDNAs and cDNA expression. Protein Eng 1990; 3:571-575.
24. Harris JW, Rahman A, Kim B-R, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994; 54:4026-4035.
25. Jamis-Dow CA, Klecker RW, Katki AG, Collins JM. Metabolism of taxol by human rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Phamacol 1995; 36:107-114.
26. Kocarek TA, Schuetz EG, Strom SC, Fisher RA, Guzelian PS. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Disp 1995; 23:415-421.
27. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 1991; 101:1680.
28. Lavelle F, Bissery M-C, Combeau C, Riou JF, Vrignaud P, André S. Preclinical evaluation of docetaxel (taxotere). Seminars Oncol 1995; 22(Suppl 4):3-16.
29. Marlard M, Gaillard C, Sanderink GJ. Kinetics, distribution, metabolism and excretion of radiolabelled taxotere®, RP 56976) metabolizing enzymes and metabolic drug-drug interactions in vitro. Proc Int Soc Xenobiotics 1993a; 3:55.
30. 14C-RP 56976, docetaxel) in mice and dogs. Proc Am Cancer Res 1993b; 43:393.
31. Marre F, de Sousa G, Placidi M. In vitro metabolism of taxotere by human hepatic cells and microsomes: involvement of CYP3A family. Proc Int Soc Xenobiotics 1993; 3:36.
32. Monegier B, Gaillard C, Sablé S, Vuilborgne M. Structures of the major human metabolites of docetaxel. Tetrahedron Lett 1994; 35:3715-3718.
33. Monsarrat B, Mariel E, Cros S, Garès M, Guénard D, Guéritte-Voegelein F, Wright M. Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab Disp 1990; 18:895-901.
34. Murray M, Butler AM, Stupans I. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6β-hydroxylation activity by cyclophosphamide and isofamide in vitro. J Pharmacol Exp Ther 1994; 270:645-649.
35. Nelson DR, Koymans L, Kamataki T, Stegenman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6:1-42.
36. Omura T, Sato R. The carbon monooxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964; 239:2370-2378.
37. Oosterom ATV, Schriivers D. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part II: clinical experience. Anti-Cancer Drugs 1995; 6:356-368.
38. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992; 41:1047.
39. Ravdin PM, Valero V. Review of docetaxel (taxotere), a highly active new agent for the treatment of metastatic breast cancer. Seminars Oncol 1995; 22 (Suppl 4):17-21.
40. Ringel I, Horwitz SB. Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. Experiment Therap 1987; 242:692-698.
41. Ringel I, Horwitz SB. Studies with RP56976 (Taxotere): a semisynthetic analog of taxol. J Natl Cancer Inst 1991; 83:288-291.
42. Rover I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56:58-65.
43. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A, Kaye S. Coping with toxicities of docetaxel (Taxotere® TM). Ann Oncol 1993; 4:610-611.
44. Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 1997; 18:207-214.
45. Spatzenegger M, Jaeger, W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 1995; 27:397-417.
46. Vani MC, Taylor HI, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI: the isolation and stucture of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1991; 93:2325-2327.
47. Vogel M, Hilsenbeck H, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, et al. Preclinical activity of taxotere (RP56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer 1995; 29:2009-2014.
48. Wang PP, Beaune P, Kaminsky LS, Dannan GA, Kadlubar FF, Larrey D, Guengerich FP. Purification and characterization of six cytochrome P450 isoxymes from human liver microsomes. Biochemistry 1983; 22:5375-5383.
49. Yun CH, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 1991; 40:679-685.
50. Zhou XJ, Xhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol 1993; 45:853-861.